BRPI0920069A2 - biomarcadores - Google Patents

biomarcadores

Info

Publication number
BRPI0920069A2
BRPI0920069A2 BRPI0920069A BRPI0920069A BRPI0920069A2 BR PI0920069 A2 BRPI0920069 A2 BR PI0920069A2 BR PI0920069 A BRPI0920069 A BR PI0920069A BR PI0920069 A BRPI0920069 A BR PI0920069A BR PI0920069 A2 BRPI0920069 A2 BR PI0920069A2
Authority
BR
Brazil
Prior art keywords
biomarkers
Prior art date
Application number
BRPI0920069A
Other languages
English (en)
Inventor
R Wagner Daniel
Azuaje Francisco
Vausort Mélanie
Devaux Yvan
Original Assignee
Centre De Rech Public De La Santé
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre De Rech Public De La Santé filed Critical Centre De Rech Public De La Santé
Publication of BRPI0920069A2 publication Critical patent/BRPI0920069A2/pt
Publication of BRPI0920069A8 publication Critical patent/BRPI0920069A8/pt

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0920069A 2008-10-30 2009-10-30 Biomarcadores BRPI0920069A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10964908P 2008-10-30 2008-10-30
PCT/EP2009/064410 WO2010049538A1 (en) 2008-10-30 2009-10-30 Biomarkers

Publications (2)

Publication Number Publication Date
BRPI0920069A2 true BRPI0920069A2 (pt) 2017-06-06
BRPI0920069A8 BRPI0920069A8 (pt) 2017-10-03

Family

ID=41528764

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920069A BRPI0920069A8 (pt) 2008-10-30 2009-10-30 Biomarcadores

Country Status (9)

Country Link
US (2) US20110294683A1 (pt)
EP (1) EP2362942B1 (pt)
JP (1) JP5749171B2 (pt)
CN (1) CN102203606A (pt)
BR (1) BRPI0920069A8 (pt)
CA (1) CA2741117A1 (pt)
ES (1) ES2640900T3 (pt)
RU (1) RU2545757C2 (pt)
WO (1) WO2010049538A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012014268A (es) 2010-07-09 2013-02-12 Somalogic Inc Biomarcadores de cancer de pulmon y usos de los mismos.
EP2603622A4 (en) 2010-08-13 2015-04-22 Somalogic Inc BIOMARKERS FOR PANCREATIC CANCER AND USES THEREOF
EP2592422A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
EP2592423A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
JP2014207883A (ja) * 2013-03-27 2014-11-06 国立大学法人岡山大学 がん幹細胞及びその用途
WO2014191553A2 (en) * 2013-05-31 2014-12-04 Cobiores Nv Heart failure treatment
EP2843414B1 (en) 2013-08-26 2018-09-19 Roche Diagniostics GmbH Marker for statin treatment stratification in heart failure
CN103487586B (zh) * 2013-09-04 2015-07-15 石家庄洹众生物科技有限公司 一种定量检测可溶性生长刺激表达蛋白2的试验装置
PL228091B1 (pl) * 2014-02-12 2018-02-28 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Zestaw biomarkerów transkryptomicznych do zastosowania w stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolnosci serca, sposób diagnozowania ryzyka wystapienia u pacjenta pozawałowej niewydolnosci serca i zastosowanie biomarkerów do diagnostyki in vitro
WO2015183601A1 (en) 2014-05-28 2015-12-03 Scripps Health Predictive analysis for myocardial infarction
CN105243294B (zh) * 2015-09-18 2017-06-09 淮南师范学院 一种用于预测癌症病人预后相关的蛋白质对的方法
RU2634375C2 (ru) * 2016-04-18 2017-10-26 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт кардиологии" Способ предупреждения постинфарктного ремоделирования сердца в эксперименте
CA3030038A1 (en) * 2016-07-06 2018-01-11 Guardant Health, Inc. Methods for fragmentome profiling of cell-free nucleic acids
DE102017116204B4 (de) * 2017-07-18 2024-06-27 Universität Rostock Verfahren zur Vorhersage der Antwort auf die kardiovaskuläre Regeneration
US11708600B2 (en) * 2017-10-05 2023-07-25 Decode Health, Inc. Long non-coding RNA gene expression signatures in disease diagnosis
JP2022549479A (ja) * 2019-09-30 2022-11-25 エフ．ホフマン－ラ ロシュ アーゲー 疾患状態の予測方法
JP7489059B2 (ja) * 2020-04-21 2024-05-23 国立大学法人横浜国立大学 画像生成装置、表示装置、画像生成方法、提示方法およびプログラム
US11854675B1 (en) 2022-10-11 2023-12-26 Flatiron Health, Inc. Machine learning extraction of clinical variable values for subjects from clinical record data
US11915807B1 (en) * 2022-10-11 2024-02-27 Flatiron Health, Inc. Machine learning extraction of clinical variable values for subjects from clinical record data

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513780A (en) * 1999-03-03 2001-09-28 Ludwig Inst Cancer Res Heart abnormalities in vascular endothelial growth factor B (VEGF-B) deficient animals and methods relating to these heart abnormalities
CN1139811C (zh) * 1999-11-09 2004-02-25 赵永同 肿瘤早期检测评估试剂盒及其制备工艺
CN1260492A (zh) * 1999-11-09 2000-07-19 赵永同 肿瘤预后评估试剂盒及其制备工艺
ATE315789T1 (de) * 1999-11-16 2006-02-15 Genentech Inc Elisa für vegf
CA2409948A1 (en) * 2000-05-17 2001-11-22 Xuri Li Methods for detecting for the presence of tumor cells and for screening for anti-tumor agents
WO2003000009A2 (en) * 2001-06-20 2003-01-03 Ludwig Institute For Cancer Research Stimulation of vascularization with vegf-b
CN100401063C (zh) * 2001-08-13 2008-07-09 遗传学发展股份有限公司 选择人类肿瘤最佳疗法的分子诊断和计算机决策辅助系统
US20030096248A1 (en) * 2001-09-04 2003-05-22 Vitivity, Inc. Diagnosis and treatment of vascular disease
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
DE50309809D1 (de) * 2002-11-16 2008-06-19 Dade Behring Marburg Gmbh Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
US8632994B2 (en) * 2003-12-01 2014-01-21 Dako Denmark A/S Methods and compositions for immuno-histochemical detection
CN101426489A (zh) * 2004-04-16 2009-05-06 曹义海 抑制血管生成的成分和方法
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
TW200732347A (en) * 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use

Also Published As

Publication number Publication date
JP2012507026A (ja) 2012-03-22
CA2741117A1 (en) 2010-05-06
BRPI0920069A8 (pt) 2017-10-03
EP2362942B1 (en) 2017-06-21
RU2011121613A (ru) 2012-12-10
US20160188835A1 (en) 2016-06-30
CN102203606A (zh) 2011-09-28
RU2545757C2 (ru) 2015-04-10
EP2362942A1 (en) 2011-09-07
US20110294683A1 (en) 2011-12-01
WO2010049538A1 (en) 2010-05-06
ES2640900T3 (es) 2017-11-07
JP5749171B2 (ja) 2015-07-15

Similar Documents

Publication Publication Date Title
FIC20250022I1 (fi) Atetsolitsumabi
FIC20220024I1 (fi) Anifrolumabi
NL300965I2 (nl) Patisiran
NL300961I2 (nl) Erenumab
FIC20170031I1 (fi) alirokumabi
DK2370462T3 (da) Glucagon-analoger
DK2342317T3 (da) Hængende-dråbe-plade
BRPI0907376A2 (pt) Fotobiorretador
EP2265642A4 (en) BIOMARKERS
DK3444343T3 (da) Polypeptider
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
EP2245464A4 (en) P53 BIOMARKERS
DK2379557T3 (da) Aminopyrazol-forbindelse
DK2271613T3 (da) Hydroxymethylcyklohexylaminer
EP2257170A4 (en) TETRAHYDROFUROPYRIDONE
EP2263086A4 (en) BIOMARKERS
EP2339366A4 (en) DEVICE FOR OPTICAL DISTANCE MEASUREMENT
DE602009000862D1 (de) Gehwagenbremse
DE112009001946A5 (de) Mobelauszugsführung
BRPI0909637A2 (pt) 2-aminoquinolinas
EP2265641A4 (en) BIOMARKERS
FI20080325A0 (fi) Pihkaliuos
DK2517018T3 (da) Biomarkører
FIU20080263U0 (fi) Suunhoitovalmiste
FI8146U1 (fi) Luontaislämpölattia

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: LUXEMBOURG INSTITUTE OF HEALTH (LU)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2486 DE 28-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.